DUBLIN--(BUSINESS WIRE)--The "Global Sexually Transmitted Diseases (STD) Treatment Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.
The sexually transmitted diseases (STD) treatment market will register a CAGR of more than 4% by 2023.
The increasing prevalence of STDs is one of the key factors expected to trigger the market's growth in the forthcoming years. STDs are rising in the emerging and advanced economies, resulting in the rising demand for drugs and therapies for treating these chronic illnesses.
The cases of these incidences has increased considerably in the recent years owing to the transmission of different bacteria, viruses, and parasites during sexual contact. As a result, the increasing prevalence of STDs will further propel the demand for drugs and therapies, in turn, contributing significantly to the STD treatment market growth during the forecast period.
Market Overview
Approval of drugs and a strong pipeline
One of the growth drivers of the global sexually transmitted diseases (STD) treatment market is the approval of drugs and a strong pipeline. With the increase in prevalence and incidence of STDs, market players are focused on the development of therapies to treat these diseases. The market has witnessed new drug approvals, which will drive the market during the forecast period.
Social stigma associated with STDs
One of the challenges in the growth of the global sexually transmitted diseases (STD) treatment market is the social stigma associated with STDs. The social stigma associated with STDs can lead to reduced screening, prevention, and care, thereby hindering the growth of the market.
Competitive Landscape
The market appears to be moderately fragmented with the presence of several market players. Many government organizations are collaborating with commercial companies to develop HIV vaccines. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.
Key Topics Covered:
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 04: MARKET SIZING
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 06: MARKET SEGMENTATION BY TYPE
- Market segmentation by type
- Comparison by type
- Viral infections - Market size and forecast 2018-2023
- Bacterial infections - Market size and forecast 2018-2023
- Other infections - Market size and forecast 2018-2023
- Market opportunity by type
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2018-2023
- Europe - Market size and forecast 2018-2023
- Asia - Market size and forecast 2018-2023
- ROW - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
- Overview
- Landscape disruption
PART 13: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Bristol-Myers Squibb Company
- Gilead Sciences, Inc.
- GlaxoSmithKline plc
- Johnson & Johnson Services, Inc.
- Merck & Co., Inc.
PART 14: APPENDIX
For more information about this report visit https://www.researchandmarkets.com/r/gzo5j
